

---

**Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate**

*All Wales Medicines Strategy Group (AWMSG)*

---

**Record Status**

This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

**Citation**

All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). 2003

**Final publication URL**

<http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371& id=176044& pid=24773>

**Indexing Status**

Subject indexing assigned by CRD

**MeSH**

Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoids

**Language Published**

English

**Country of organisation**

Wales

**English summary**

An English language summary is available.

**Address for correspondence**

All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX Email: AWTTC@wales.nhs.uk

**AccessionNumber**

32012000481

**Date abstract record published**

08/08/2012